---
title: 'Senior Research Associate, Preclinical Pharmacology at Nurix'
canonical: 'https://feeny.ai/job/senior-research-associate-preclinical-pharmacology-nurix-brisbane-whtmqmhser7g'
type: 'job'
last_seen: '2026-10-15'
---

# Senior Research Associate, Preclinical Pharmacology at Nurix

- **Company:** Nurix
- **Location:** Brisbane, CA
- **Posted:** 2026-10-14
- **Last confirmed live:** 2026-10-15
- **Apply:** https://job-boards.greenhouse.io/nurix/jobs/8887158002

## Job description

Senior Research Associate, Preclinical Pharmacology

Run in vivo studies that move Nurix's degrader programs toward the clinic. You'll execute mouse efficacy, PK/PD, and mechanism-of-action studies in oncology and inflammation models and generate the Western blot and flow cytometry data that show how our molecules work.

Position Description

The Opportunity

- Join the Research – Preclinical Pharmacology team as a full-time, onsite, hands-on member, reporting to a Scientist / Principal Scientist, Preclinical Pharmacology
- Perform mouse handling and in-life procedures, including dosing by oral (PO), intraperitoneal (IP), subcutaneous (SC), and intravenous (IV) routes, tumor cell implantation, tumor and body-weight measurements, and in-life and terminal blood collection
- Execute PK/PD, tolerability, and efficacy studies in oncology xenograft/syngeneic models and in murine models of inflammation, under the direction of study leads
- Prepare and formulate test articles and vehicles for dosing; monitor animal health, document observations, and escalate adverse events promptly
- Perform necropsy and collect, process, and bank tissues and blood for downstream biomarker and pharmacodynamic analyses
- Prepare tissue and cell lysates and perform Western blotting (including quantitative and automated capillary formats) to measure target degradation and pathway modulation
- Develop, run, and analyze multi-color flow cytometry panels for immune and tumor-cell phenotyping from blood, spleen, tumor, and other tissues
- Maintain and expand cell lines using sterile cell culture technique; support cell-based assays and the generation of cells for in vivo implantation
- Record experiments accurately and in a timely manner in the electronic lab notebook; analyze, graph, and summarize data and present results at team meetings
- Collaborate with Biology, Chemistry, DMPK, and Translational teams to design studies and troubleshoot models and assays
- Adhere to IACUC protocols, animal welfare regulations, and laboratory safety requirements, and maintain required training and certifications
- Contribute to the optimization and qualification of new models and assays and to the training of junior team members
- Maintain laboratory equipment and supplies and support vivarium coordination, including occasional weekend or off-shift study coverage; other essential duties as assigned; minimal travel (<5%)

## What You’ll Bring

- BS/MS in Biology, Pharmacology, Immunology, Cancer Biology, or a related field, with a BS or equivalent plus 8 or more years of relevant experience, or an MS plus 4 or more years of relevant experience
- Industry (biotech or pharma) experience conducting in vivo pharmacology studies in mice
- Proficiency in mouse handling and dosing by PO, IP, SC, and IV routes, as well as blood collection and tissue harvest
- Hands-on experience with oncology models (e.g., xenograft, syngeneic) and with murine models of inflammation or immunology
- Demonstrated proficiency in Western blotting and flow cytometry, including sample preparation, staining, and data analysis
- Proficiency in sterile mammalian cell culture technique
- Working knowledge of IACUC regulations and humane animal care practices
- Strong organizational and documentation skills, with attention to detail and the ability to manage multiple studies simultaneously
- Collaborative, adaptable, and comfortable in a fast-paced, team-oriented research environment
- Ability to work in an animal facility and tolerate exposure to laboratory animals, and to work occasional weekends or off-shift hours as studies require
- Bonus: experience with targeted protein degradation (molecular glues, PROTACs) or other small-molecule oncology or immunology programs
- Bonus: experience with multi-spectral flow cytometry, automated Western (e.g., Jess/Wes), ELISA, or MSD cytokine/biomarker assays
- Bonus: experience with orthotopic, disseminated, PDX, or humanized mouse models, or with in vivo imaging
- Bonus: experience with inflammation models such as collagen-induced arthritis, colitis, or cytokine-challenge models
- Bonus: familiarity with PK/PD relationships, compound formulation, and dose-response study design
- Bonus: proficiency with GraphPad Prism and electronic lab notebook systems

Salary Range:  $131,400 - $139,900

The posted range applies to roles based in the San Francisco Bay Area and reflects local market conditions. Where an offer lands within that range depends on the candidate’s relevant experience, technical expertise, and how their background aligns with the role’s requirements.

Location:          Onsite – Brisbane, CA

Fit with Nurix Culture and Values

- Strong team orientation; highly collaborative
- Solutions and results-oriented focus
- Hands-on approach; resourceful and open to diverse points of view

## About Nurix Therapeutics

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.

## About Nurix

## Company Overview
- **One-liner**: Nurix Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines to outmatch disease by harnessing the cell’s natural protein disposal system.
- **Entity Type**: Public (NASDAQ: NRIX)
- **Headquarters**: San Francisco, California, USA
- **Founded**: 2009
- **Founders**: Not publicly listed as individual founders; the company was spun out from research at UC Berkeley and UC San Francisco.

## Core Business
- **Primary industry**: Biopharmaceuticals / Targeted Protein Degradation
- **Target customers**: B2B (pharma partners) and B2C (patients via clinical trials and eventual commercial therapies); enterprise-level partnerships with major pharma.
- **Mission or purpose statement**: "Writing medicine’s next chapter using targeted protein degradation as a new script to outmatch disease." [nurixtx.com](https://www.nurixtx.com/)

## Products & Services
- **Bexobrutideg (NX-5948)**: A potential best-in-class BTK degrader in Phase 1b/2 clinical trials for relapsed/refractory CLL/SLL and chronic spontaneous urticaria. Co-developed and co-commercialized with Roche under a global collaboration announced June 2026. [nurixtx.com](https://www.nurixtx.com/)
- **NX-2127**: A BTK degrader in clinical development for B-cell malignancies.
- **CBL-B Inhibitor (NX-1607)**: An E3 ligase inhibitor designed to activate T cells for immuno-oncology, in Phase 1 clinical trials.
- **IRAK4 Degrader**: A partnered program with Gilead in Phase 1 for inflammatory diseases.
- **STAT6 Degrader**: A partnered program with Sanofi in IND-enabling studies.
- **DEL-AI Discovery Engine**: A proprietary, fully AI-integrated platform combining DNA-encoded libraries (DEL), automated chemistry, and machine learning to design and optimize targeted protein degraders and degrader-antibody conjugates (DACs).

## Market Standing
- **Valuation/Market Cap**: Not publicly available in the provided search results; as a public company (NRIX), market cap fluctuates daily. Check financial platforms for the latest figure.
- **Key Metric**: Annual Revenue (public) — Not publicly available in the provided search results; as a clinical-stage biotech, revenue is typically minimal or pre-revenue. Total funding raised prior to IPO is not detailed in the provided results.
- **Notable Investors/Partners**: Roche (global co-development and co-commercialization collaboration for bexobrutideg, announced June 2026), Gilead (partnered IRAK4 degrader program), Sanofi (partnered STAT6 degrader program).
- **Growth Signals**: Announced a landmark global collaboration with Roche in June 2026 to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology. Presented positive Phase 1a/b data for bexobrutideg in CLL/SLL and chronic spontaneous urticaria in 2026. Multiple partnered and wholly owned pipeline programs advancing through clinical and preclinical stages.

## Competitive Advantages
- **Proprietary DEL-AI Discovery Engine**: A fully AI-integrated platform combining DNA-encoded libraries, automated chemistry, and machine learning to design degraders against any protein class, providing a significant speed and innovation advantage. [nurixtx.com](https://www.nurixtx.com/)
- **Unparalleled Ligase Expertise**: Deep understanding of E3 ligase biochemistry and biology, a critical and complex component of the protein degradation mechanism, giving them a unique moat.
- **Multi-Modal Pipeline**: Developing both small molecule degraders and Degrader-Antibody Conjugates (DACs), expanding the therapeutic reach and creating multiple shots on goal.
- **Strong Partnership Network**: Collaborations with top-tier pharma (Roche, Gilead, Sanofi) validate their platform and provide non-dilutive funding and shared risk.

## Strategic Focus
- **Clinical Advancement**: Driving lead asset bexobrutideg through pivotal trials in CLL/SLL and expanding into immunology (chronic spontaneous urticaria) and neurology.
- **Platform Expansion**: Leveraging the DEL-AI engine to develop Degrader-Antibody Conjugates (DACs) for enhanced cell specificity and safety.
- **Pipeline Breadth**: Advancing a multi-modal pipeline across oncology, immunology, and neurology, both wholly owned and through strategic partnerships.
- **Partnership Leverage**: Deepening collaborations with Roche, Gilead, and Sanofi to co-develop and co-commercialize programs, reducing risk and accelerating timelines.

## Why Work Here
- **Culture**: Mission-focused, values-based, and spirited culture emphasizing "breakthrough innovation," "leadership," "accountability," and "zealousness." Employees are encouraged to "think big and act bold." [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Work with Industry Leaders**: The team includes scientific innovators who built the protein degradation field, seasoned executives with biotech scaling expertise, and leading clinicians. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Growth & Impact**: Employees can "wear many hats" and gain broad exposure in a lean, virtual drug developer environment. The company emphasizes career growth and opportunity-rich experiences.
- **Work Policy**: Onsite in Brisbane, CA (San Francisco Bay Area) for most roles, as indicated by job postings. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
- **Benefits**: Comprehensive health and welfare plans, enhanced parental leave, wellness reimbursement, 401(k) employer match, and a highly collaborative culture. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
- **Engineering/Science Culture**: Described as "mission-focused, values-based, and spirited," with a focus on "intellectual and technical ingenuity" and "intelligent risk-taking." The company is a "virtual drug developer" with a lean internal infrastructure, relying on SaaS and cloud platforms. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)

## Sources
1. [nurixtx.com](https://www.nurixtx.com/)
2. [nurixtx.com](https://www.nurixtx.com/work-at-nurix/)
3. [nurixtx.com](https://www.nurixtx.com/explore-jobs/)
4. [nurixtx.com](https://www.nurixtx.com/our-story/)

## Other roles at Nurix

- [Senior Scientist, Medicinal Chemistry](https://feeny.ai/job/senior-scientist-medicinal-chemistry-nurix-the-woodlands-y4nmgjxktsm5) — The Woodlands, TX
- [Scientist I, Medicinal Chemistry](https://feeny.ai/job/scientist-i-medicinal-chemistry-nurix-the-woodlands-bxgy2c1m60vz) — The Woodlands, TX
- [Senior Director, Head of Pharmacovigilance Operations](https://feeny.ai/job/senior-director-head-of-pharmacovigilance-operations-nurix-brisbane-qvx5sf5gc0cv) — Brisbane, CA
- [Senior Manager / Associate Director, Regulatory Affairs CMC (Small Molecules)](https://feeny.ai/job/senior-manager-associate-director-regulatory-affairs-cmc-small-molecules-nurix-pp3fh8jc68k1) — Brisbane, CA
- [Administrative Assistant, Clinical Development (Contract)](https://feeny.ai/job/administrative-assistant-clinical-development-contract-nurix-brisbane-6rnsp2fj2vte) — Brisbane, CA
- [Administrative Assistant, CMC (Contract)](https://feeny.ai/job/administrative-assistant-cmc-contract-nurix-brisbane-cgkssyzb35sq) — Brisbane, CA
- [Principal Engineer, Pharmaceutical Development](https://feeny.ai/job/principal-engineer-pharmaceutical-development-nurix-brisbane-gafzcr3nzvks) — Brisbane, CA
- [Associate Director, Regulatory & Medical Writing](https://feeny.ai/job/associate-director-regulatory-medical-writing-nurix-brisbane-2ges8w25nvka) — Brisbane, CA
- [Director, Drug Safety](https://feeny.ai/job/director-drug-safety-nurix-brisbane-6cvez55232p3) — Brisbane, CA
- [Talent Acquisition Analyst - Contract](https://feeny.ai/job/talent-acquisition-analyst-contract-nurix-brisbane-158rrae5f57v) — Brisbane, CA